The New England Journal of Medicine

A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide

Enlicitide decanoate, an oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, was shown to reduce low-density lipoprotein (LDL) cholesterol levels in a phase 2 trial; longer-term data ...
The New England Journal of Medicine

Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease

Despite guideline recommendations, evidence from randomized trials evaluating the appropriate low-density lipoprotein (LDL) cholesterol target for secondary prevention in patients with atherosclerotic ...
The American Journal of Managed Care

Oral PCSK9 Inhibitor Enlicitide Lowers LDL by 57% at 24 Weeks

CORALreef Lipids randomized 2,909 adults (2:1) to enlicitide 20 mg daily or placebo across 168 sites, using stratification by renal function, baseline statin use, and region. LDL-C at week 24 ...
Business Wire

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef Lipids ...
Business Wire

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced detailed results from CORALreef AddOn, an active comparator study designed to ...